

Annual Review 2021

Creating opportunities across the UK

ct.catapult.org.uk/annualreviews

Contents

Introduction.....	3
Stimulating and supporting innovation in the UK.....	10
Accelerating UK growth	14
Supporting the COVID-19 pandemic response	18
Driving industry skills development	22
Accelerating patient access.....	24
Looking forward	28
Financial highlights	30

Our vision

A thriving industry delivering life-changing advanced therapies to the world.

Our role

Our role is to create powerful collaborations which overcome challenges to the advancement of the sector.

How we work

We are a team of experts covering all aspects of advanced therapies. Applying our unique capabilities and assets, we collaborate with academia, industry and healthcare providers to develop new technology and innovation.

Our impact


Our outputs leverage research, transform barriers into industrial advantage, and attract investment for our collaborators.

We help people acquire new skills, organisations establish new capabilities and policy makers develop new perspectives.



2020/21 Cell and Gene Therapy Catapult Outputs and Outcomes

3,800



people up-skilled

132



total projects

88



companies collaborated with us
(44% of which are UK SMEs)

25



universities and research institutes
with which we have worked

104



companies being supported
with up-skilling

38



International collaborations

£525m



raised by our UK
collaborators in Stevenage

£900m



in financing raised by our
UK collaborators


21




companies supported that are
conducting clinical trials

UK Industry Growth


Investment in ATMPs since 2012



ATMP GMP Manufacturing space




Jobs




* Partial data as available at time of print

Phase III clinical trials



Reimbursed therapies reaching patients



Chairman's statement

The events of the past year have shown the true strength of the UK cell and gene therapy industry. Even with disruption from the COVID-19 pandemic, expansion in this sector was significant. This was demonstrated by the UK GMP manufacturing space for cell and gene therapies increasing by 48% in 2020. The industry is certainly on its way to achieving and indeed exceeding the anticipated 4,000 jobs and £2bn in revenue by 2025.

We have seen an increase in the UK manufacturing footprint and number of clinical trials including in the cell and gene therapy cluster around Stevenage. Cell and Gene Therapy Catapult (CGT Catapult) has been able to support these developments in the production and commercialisation of transformative therapies. The Stevenage advanced therapies campus, this year named a High Potential Opportunity Zone by the Department for International Trade in recognition of its thriving cell and gene therapy activities, we believe will bring even further opportunities for growth.

The CGT Catapult is having a growing impact across the sector thanks to the continued support of the UK Government.

The CGT Catapult received £127m grant funding to setup a facility in Braintree to increase the UK

“ We look forward to using the Braintree facility to provide the UK with additional long-term capabilities for cell and gene therapy innovation. ”

preparedness for pandemics and increase innovation in vaccine and cell and gene therapies manufacturing.

We look forward to using this facility to provide the UK with additional long-term capabilities for cell and gene therapy manufacturing innovation.

I would like to thank all our partners from Government, industry, and academia for their invaluable contribution to the growth and strength of the industry. I would also like to thank the CGT Catapult team, who have done a tremendous job to support the industry throughout the last year as we embrace new ways of working.



*Dr John Brown CBE,
FRSE Chairman*



Chief Executive Officer's statement

We have continued to make significant progress, including increasing our manufacturing innovation capabilities with the establishment of a new facility in Braintree. Through all of the adversities of the last year we have driven and enabled national and international investment into the UK cell and gene therapy industry.

Our collaborations with the UK research sector have accelerated promising research into commercial development. We have established the Advanced Therapies Skills Training Network to up-skill the industry's and the vaccine industry's existing workforce and attract new talent. As a result of our collaborations in London and Stevenage, we have seen greater national and international investment into advanced therapy manufacturing than ever before. The Advanced Therapies Treatment Centres are increasing the NHS

“ It has been extremely rewarding to work so closely with the industry through this year, and we look forward to leveraging our new partnerships and connections to accelerate a thriving UK industry. ”

readiness and robustness necessary to reliably and cost effectively bring these life changing therapies to more patients.

As a result of the increased demand for collaboration our team has increased by over a third to **370** experts. After such a challenging year I would like to thank every one of them for their persistence and achievement.

We are excited for the year ahead, particularly as the UK emerges from the pandemic. It has been extremely rewarding to work so closely with the industry through this year, and we look forward to leveraging our new partnerships and connections to accelerate a thriving UK industry which is delivering advanced therapies to the world.



*Matthew Durdy,
Chief Executive Officer*

The UK: place of choice to set up ATMP activities

29%



European ATMP companies operating in the UK

12%



of global ATMP clinical trials represented in the UK

£3.8bn



Investment received by ATMP companies since 2012

20%



increase in clinical trials in the UK compared to previous year

11



global pharmaceutical companies developing ATMPs with UK presence

26



GMP manufacturing facilities

99



advanced therapy developers

UK



Largest cell and gene therapy cluster outside the US

12



EMEA licensed ATMPs available




CATAPULT

Cell and Gene Therapy

Innovating through collaboration

67 collaborative projects



to support cell and gene therapy development, bringing investment and productivity

54%

of collaborative projects carried out with UK SMEs



Facilitating growth of the UK ATMP ecosystem

11x

the leverage shown by the £850m investment into our collaborators in Stevenage following £72m IUK investment in our Manufacturing Innovation Centre



£127m

investment into CGT Catapult facility in Braintree to accelerate industrial scale manufacturing innovation



7%

of global ATMP clinical trials are active in the Advanced Therapy Treatment Centres



15 ATMP apprenticeship programmes

137 Advanced Therapies Apprenticeships Community (ATAC) apprentices employed by 37 UK companies



Complementing industry and academia

63 core research projects

building capabilities and providing novel technologies to researchers and industry



Accelerating commercialisation of ATMP research

30 Commercial Readiness

Advice Clinics provided to early-stage companies



Collaborations

with 88 companies and 21 universities



- CGT Catapult offices
- Midland and Wales ATTC partners
- ATSTN, National Training Centres partners

- iMatch ATTC partners
- Northern Alliance ATTC partners

Stimulating and supporting innovation in the UK

Supporting SMEs and technology development

The UK's strong research and academic capabilities remain a key asset that continues to fuel growth of the cell and gene therapy industry. By connecting researchers, investors and industry we accelerate innovation in the sector.

Case study: Applying viral vector process manufacturing innovation to therapy development

CGT Catapult has supported NHS Blood and Transplant and The University of Sheffield in successful competitive bids for a share of the £18m released by the Medical Research Council and LifeArc for the development of hubs to manufacture viral vector drug substance for gene therapy clinical trials.

The hubs will be founded on the CGT Catapult developed adeno-associated viral vector manufacturing and analytical platform.

Case study: Connecting the industry through the Process Analytical Technology (PAT) Consortium

The challenge: accounting for biological variability which can result in variable product quality.

The solution: CGT Catapult has created a consortium of over 20 organisations to produce new analytical methods that can be applied in real time to allow manufacturing changes that will improve product consistency.

Impact: By sharing their knowledge and expertise, this consortium is creating data to allow optimisation and comparison of nine different biological sensors. This will allow equipment manufacturers and therapy developers to apply the most appropriate technology to their medicines development, contributing to the production of safer and higher quality therapies at a lower cost.



Case study: The University of Sheffield awarded £500k from LifeArc



The University of Sheffield's group was progressing towards clinical trials with their new adeno-associated viral vector based therapy targeting the SRSF1 gene to treat Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD).

CGT Catapult staff worked with The University of Sheffield team over the course of several months to refine the development plan into a stronger value proposition with a clear translational roadmap, non-clinical report, intellectual property review and health economics consultation; all which facilitated the award of £500k from LifeArc to progress this research into clinical trials.



*Dr Jonathan Appleby,
Chief Scientific Officer*

“ We are extremely proud of the scientific team at the CGT Catapult. They continually impress me with their breadth of knowledge, inventiveness and dedication. ”



Stimulating and supporting innovation in the UK

Supporting SMEs with Commercial Readiness Advice Clinics

CGT Catapult has been supporting spin-out companies as well as small and medium sized enterprises (SMEs) through Commercial Readiness Advice Clinics since 2018, following £3.36m in grant funding from the European Regional Development Fund (ERDF).

The clinics give ERDF-funded access to CGT Catapult's expertise to help companies progress through the commercialisation path from innovation towards a reimbursed product.

To date, 30 cell and gene therapy developers and technology companies, eight of these under 12-months old, have received tailored advice through the Commercial Readiness Advice Clinics to progress their projects. CGT Catapult has continued to support a number of these companies with follow-on work funded through other grants as part of jointly funded collaborative projects.

Following the overwhelming success of these clinics, CGT Catapult will continue to offer commercial readiness advice clinics beyond the ERDF's grant funding period. This will ensure more SMEs will be able to benefit from the unique offering from CGT Catapult providing advice to facilitate progression, from inception through to commercialisation.

“ The Commercial Readiness Advice Clinics have offered tangible benefits to the companies we have worked with and are now a well-established part of the CGT Catapult's unique offering ”



*Dr Sharon Brownlow,
Chief Business Officer*



European Union
European Regional
Development Fund


Progress so far from companies benefiting from the Commercial Readiness Advice Clinics through ERDF support

19



new jobs created

5



new product prototypes developed



3



collaborations completed
with research institutes

30



Cell and gene therapy
developers supported

8



of which were under 12 months old

Case study: See-Through Scientific Ltd.
refining prototype for market needs

See-Through Scientific Ltd. worked with CGT Catapult via the Commercial Readiness Advice Clinics on the continued development of their next-generation holographic microscopy systems for cell analysis.

The technology development scientists at CGT Catapult provided detailed technical knowledge to guide prototype improvement. These key design decisions resulted in an enhanced product with a distinct competitive edge.

Case study: Drishti Discoveries
becomes investment ready

Through the Commercial Readiness Advice Clinics, CGT Catapult were able to provide expertise to support Drishti Discoveries on their journey to secure the first investors into their innovative RNAi technology for use in gene therapies.

Accelerating UK growth

Progressing academic research into commercial opportunities

Working with academia to translate research into commercial opportunities, CGT Catapult's capabilities enable academic institutions to attract investment to progress novel life changing therapies.

Case study: Collaborating with King's College London to deliver commercial scale production of viral vectors

The Rayne Cell Therapy Suite at King's College London collaborated with CGT Catapult to optimise the production of adeno-associated viral vectors at clinical scale.


The CGT Catapult team worked to enhance the throughput and productivity whilst reducing cost, compared to other established batched adherent cell culture-based systems.



This project resulted in an automated and refined manufacturing process with:

1,000-fold

Up to 1,000-fold reduction in manual steps per batch



>40%

increase in assay repeatability



50-90%

reduction in production time



20-fold

Up to 20-fold reduction in the cost per batch



These factors were critical in making key design decisions leading to a more competitive product.





Case study: Purespring Therapeutics received £45m financing from Syncona

CGT Catapult supported the University of Bristol in translation of their ground-breaking gene therapy technology for a rare paediatric kidney disease into an attractive investment opportunity to enable progression to the clinic.

Over an 18-month period, CGT Catapult helped the research team at Bristol to redesign the pre-clinical development plan in preparation for their MHRA submission. With a clear and defined route into clinical trials executed by the team at the University lead by Prof Moin Saleem, the resulting spin-out company, Purespring Therapeutics, secured £45m investment from Syncona. This represents one of the largest single investments to date for a new UK university biotech company.

Case study: Rinri Therapeutics selects CGT Catapult as a key preclinical development partner as they close in on the clinic

Rinri Therapeutics, a preclinical cell therapy biotechnology company based in Sheffield (UK), selected CGT Catapult to help develop its stem cell derived product to treat sensorineural hearing loss, for which there are currently no therapies. With CGT Catapult as a collaborator, Rinri secured grant funding for a £3.2m project from Innovate UK's Biomedical Catalyst scheme. The CGT Catapult team will provide crucial support to Rinri, conducting vital process development and manufacturing activities to develop GMP manufacturing and enable preclinical safety and clinical trials to begin.



purespring



The University of Sheffield.

Accelerating UK growth

Continued development of the Stevenage cell and gene therapy cluster

CGT Catapult Stevenage is at the centre of the largest cell and gene therapy cluster outside of the USA

The cell and gene therapy cluster around Stevenage is the largest outside the US, home to 75% of the UK's cell and gene therapy developers and accounting for 60% of UK ATMP GMP manufacturing footprint.

The CGT Catapult Stevenage Manufacturing Innovation Centre has been instrumental in the continuous growth of this cluster and in 2020/21 comprises:


7

collaborating companies



12

manufacturing modules



2,100m²

cleanroom footprint



Stevenage named as a High Potential Opportunity Zone for international investment

In October 2020, recognising the national and international significance of its thriving cell and gene therapy cluster, Stevenage was named as a High Potential Opportunity Zone by the UK Government's Department for International Trade.

Investment into skills growth and capacity

The Hertfordshire Local enterprise Partnership has invested £3m from their Getting Building Fund to part-fund further expansion of GCT Catapult facilities in Stevenage.

The modern state of the art facility is a valuable extension to the Stevenage cell and gene therapy cluster.

CGT Catapult will establish a state of the art Skills Laboratory offering specialist cell and gene therapy training in a mock cleanroom environment and also collaborative project work to accelerate technology transfer and the development of fully-compliant GMP manufacturing processes.





Attracting inward investment from international companies



In February 2021, the German contract development and manufacturing organisation, Rentschler Biopharma, entered into a collaboration agreement with CGT Catapult, highlighting the attractiveness in supplying ATMPs to the rest of the world from the UK.

Rentschler Biopharma will setup their facility to increase the UK ATMP development and manufacturing capabilities. The collaboration focuses on manufacturing adeno-associated viral vectors for use in clinical trials and this will further contribute to the establishment of manufacturing expertise in the UK.

Hertfordshire
Local Enterprise
Partnership



UK Research
and Innovation

Enhancing big pharma investment in cell and gene therapy manufacturing in the UK



GSK expanded its clinical trial manufacturing capacity for cell and gene therapy at the Cell and Gene Therapy Catapult facility in Stevenage. This collaboration enhanced GSK's investment in cell and gene therapy manufacturing in the UK for clinical trials bringing additional expertise to the collaborators already based at the CGT Catapult facility in Stevenage.

GSK is leveraging the CGT Catapult Stevenage facility to perform GMP cell processing to accelerate its cell and gene therapy pipeline for clinical trials, and brings additive operational excellence to benefit future and current collaborators progressing their manufacturing onsite.



Innovate
UK



European Union
European Regional
Development Fund

Supporting the COVID-19 pandemic response

Working with industry and the Vaccine Taskforce

Providing our expertise to support the UK industry in facing the pandemic.

In April 2020, the UK Government set up the Vaccine Taskforce to expedite and coordinate efforts to ensure the UK population would have access to a clinically safe and effective vaccine against COVID-19.

Since the formation of the UK Government Vaccine Taskforce, kick started by the work of the BioIndustry Association (BIA) manufacturing taskforce, CGT Catapult has been contributing to delivering safe and effective COVID-19 vaccines to the UK.

We have been able to leverage our expertise of development and manufacturing of novel therapies to expedite COVID-19 clinical trials and vaccine manufacturing.

With our expertise in viral vector manufacturing, regulation and supply chain management, we have worked closely alongside industry, academic and government organisations at the forefront of developing and manufacturing a COVID-19 vaccine, including the team at the University of Oxford, UK-based manufacturers and suppliers.

Our work with the Vaccine Taskforce, while responding to one of the most critical global health emergencies, has led to an industry that has stronger connections across the ATMP lifecycle, making the nation stronger in the event of future pandemics.



“ It has been a privilege for CGT Catapult to play a part in the national COVID-19 vaccine effort. The sheer hard work and ingenuity of so many individuals across industry, academia and government has played a significant part in our collective battle against the virus. Previous manufacturing investments in the UK’s cell and gene therapy capability and capacity have played a pivotal part in the nation’s rapid response and we look forward to building on this national legacy with colleagues from across the sector ”

“ The Vaccine Taskforce’s rapid, collective response has seen industry, academia and regulators using their shared knowledge and capability to expedite the process from clinical trials to manufacturing, doing so with the united goal of doing what is best for the country and the global population. ”



*Dr Stephen Ward,
Chief Manufacturing Officer*

Supporting the COVID-19 pandemic response

Establishing a new manufacturing innovation centre in Braintree

Developing a COVID-19 vaccine product manufacturing site and a national advanced therapies asset.

As part of the Vaccine Taskforce coordinated response across the UK for the roll-out of COVID-19 vaccines, the Department for Business, Energy and Industrial Strategy (BEIS) has invested £127m in grant funding to the CGT Catapult to establish a flexible facility to support national requirements for manufacture, and preparedness for possible future pandemics.

The initial focus of the Braintree facility is to support the COVID-19 response and subsequently to support manufacturing innovation technologies for advanced therapies.

CGT Catapult has leveraged its expertise in setting up and running MHRA licensed facilities for manufacturing at large scale, and engaged with the broader industry, to develop a flexible infrastructure and expertise that will benefit the UK in the short and long term. Building on historic capabilities already present on site including skilled workforce and specialised manufacturing space, the site is due to be fully operational by December 2021.

Specifications:

- ▶ 4,627m² facility
- ▶ 736m² large-scale GMP capacity
- ▶ Up to 2 x 3,000L bioreactors and 2 seed trains
- ▶ 10 GMP QC laboratories
- ▶ 2 segregated production modules

Large-scale manufacturing innovation capabilities:

- ▶ mRNA, viral vector, cell therapy
- ▶ MHRA license-ready
- ▶ Skilled workforce
- ▶ Manufacturing Science and Technology (MSAT), and QC capability



Case Study: Collaboration within the Catapult Network enables best use of equipment and rapid project set-up

Shortly after the Braintree site was acquired, it was identified that some state-of-the-art equipment scheduled for removal could be utilised for a new initiative at the Centre for Process Innovation (CPI), an independent organisation that translates research into successfully marketed products and a founding member of the High Value Manufacturing Catapult. By identifying how the equipment could be repurposed through the strong connections in the Catapult Network, CGT Catapult and CPI were able to embark on an equipment transfer that enabled these assets to be retained and rapidly deployed for industry, adding value and minimising waste.

CATAPULT
High Value Manufacturing



Driving industry skills development

Developing innovative programmes and learning platforms for industry



Launching the Advanced Therapies Skills Training Network (ATSTN)

Following a £4.7m award from BEIS, CGT Catapult developed the ATSTN in collaboration with industry. The ATSTN comprises of an Online Training Platform, National Training Centres and a Career Converter.

This new skills initiative is committed to creating training and employment opportunities within advanced therapies and vaccine manufacturing to respond to the industry's need for skilled workforce.

Online Training Platform

Easily develop and enhance your skillset remotely. Discover the vast range of courses and learning assets available to begin and/or progress throughout your career.

[FIND OUT MORE](#)

A purple rectangular card with a background image of a person working on a laptop. The text is white and centered.

National Training Centres

On-site training courses and sessions to provide you with the hands-on expertise to succeed in your career in advanced therapies. These centres also offer companies space to deliver their own training.

[FIND OUT MORE](#)

A teal rectangular card with a background image of a person wearing a headset. The text is white and centered.

Career Converter

Measure your skillset against different roles.

Hone-in on your transferable skills and identify training needs to assist you in kick-starting your career in advanced therapies and/or vaccine manufacturing.

[FIND OUT MORE](#)

A blue rectangular card with a background image of a person's face. The text is white and centered.

Online Training Platform

Industry and CGT Catapult have worked together to provide access to over 500 digital courses and learning resources to enhance vaccine and ATMP manufacturing skills and knowledge including technical, compliance and leadership topics.

National Training Centres

Three National Training Centres across the UK have been setup to provide hands-on ATMP specific training for industry. These centres will leverage existing training technology as well as new ones such as augmented reality and virtual reality to broaden access to training and reduce the cost of it.

Career Converter

An AI-based tool developed to attract talent from adjacent and declining industries. It identifies transferable skills and matches to career opportunities in advanced therapies and vaccine manufacturing.





ATAC Advanced Therapies Apprenticeship Community

In 2018, the Advanced Therapies Apprenticeship Community (ATAC) was setup in conjunction with the Medicines Manufacturing Industry Partnership (MMIP) following £1.5m from the Industrial Strategy Challenge Fund (ISCF).

The programme now supports **137** apprentices in **37** companies and is addressing the need to develop **300-400** new skilled workers by 2024, as outlined in CGT Catapult's 2019 Skills Survey.

Case Study: Oxford Biomedica embraces apprenticeships



Oxford Biomedica's success and rapid growth forced a reassessment of hiring strategies. Recognising the opportunity that apprenticeships schemes can offer to both employers and employees, they became one of the ATAC founding members.

With ATAC's support, Oxford Biomedica was able to better mobilise human resources to deliver vaccine and advanced therapies during the pandemic. Apprentices now provide 4% of their skilled workforce and will remain an integral part of their ongoing recruitment strategy.

40%

UK ATMP developers are part of the Advanced Therapies Apprenticeship Community



4%

of Oxford Biomedica's over 700 employees are apprentices



Accelerating patient access

Developing innovative programmes and learning platforms for the NHS

The Advanced Therapy Treatment Centres (ATTC) network up-skilling NHS staff

The ATTC network is a world's-first initiative that operates with a National Health Service (NHS), with strong collaboration with industry, to establish new frameworks and processes to develop robust systems for routine delivery of ATMPs and acceleration of clinical trials. Alongside other initiatives, such as driving standardisation and improving institutional readiness, the ATTC network has also developed training tools for the up-skilling of NHS staff in the use of ATMP. These tools have included the development of online eLearning modules (developed in association with London Advanced Therapies), an Expert Webinar Series, formal MSc courses and others, which have been used by more than 5,000 people across the NHS and industry.

The network has also secured a further £9.5m grant funding to continue to work towards delivering life-saving treatment to patients.

“ The ATTC network is having a significant impact, delivering institutional readiness, up-skilling NHS staff, and driving clinical adoption also through the 60+ companies of the industry advisory group ”



*Dr Jacqueline Barry
Chief Clinical Officer*

5,000+

People trained across
NHS and industry



Industry Advisory Group setting standards and best practice

Working with the ATTC network, the Industry Advisory Group comprises more than 60 members and works to develop standards and best practice across: procurement, labelling, logistics, ATMP adoption, clinical trial templates and GMO streamlining.

Advanced Therapies NHS Readiness Toolkit

The ATTC network delivered the first NHS Readiness Toolkit for the adoption of ATMPs.

The toolkit is a free online resource with the latest guidance and standardised templates to rapidly prepare centres running clinical trials or administering commissioned ATMPs.

Case study: Facilitating trans-Atlantic clinical trials



Working together with the CGT Catapult regulatory, clinical and non-clinical teams, Sigilon successfully gained clinical trial approval for its SIG-001 cell therapy for haemophilia A. This resulted in the UK being the first global clinical trial site for this US biotech lead product.

80+

New jobs created



3,800+

Resources downloaded



Clinical impact

310 patients receiving treatment across the ATTC network

53% UK ATMP clinical trials conducted through the ATTC network

28 new services working within the NHS

40 new projects collaborating with the NHS

12 clinical processes adopted nationally

3 clinical processes adopted internationally

Impact on industry

65 members of the Industry Advisory Group

>200 collaborations ongoing across the network

35 SMEs actively engaged with ATTCs

25 international collaborations

22 new industry partners

12 awards won

2 International companies have opened UK offices

Education impact

9 higher education institutes providing training

1 new MSc Degree

4 e-learning courses launched

1 common education platform

>5,000 people trained through education programme

9 webinars held

19 published articles



ATTC

Advanced Therapy Treatment Centres

The ATTC network currently conducts:
53% of UK ATMP clinical trials
representing 7% of global ATMP trials

Coordinated by
CATAPULT
Cell and Gene Therapy

UKRI UK Research and Innovation



Consolidating the UK ecosystem

Providing reimbursement planning and shaping the market access infrastructure

The CGT Catapult Health Economics and Market Access team has been working with industry to provide strategic reimbursement planning for ATMPs that are in development. Collaborating with diverse organisations such as the NHS Accelerated Access Collaborative and European Society for Blood and Marrow Transplantation, CGT Catapult has:

- ▶ Input into the 2020-21 NICE Methods and Processes review ensuring relevance and fit for ATMPs
- ▶ Driven digital infrastructure initiatives to optimise Real World Evidence data collection for ATMPs

- ▶ Consolidated learnings from CAR-T adoption across the NHS
- ▶ Input into the 2021 update of the CAR-T service specification
- ▶ Collated a report on the uptake of innovative payment mechanisms for ATMPs to disseminate learnings.

(<https://www.futuremedicine.com/doi/pdf/10.2217/rme-2020-0169>)

Looking forward

Investing to drive technology innovation

We will continue to work with industry to create powerful collaborations which overcome challenges to the advancement of the sector.

Supporting Stevenage collaborators into the next phase of growth

We continue to work towards facilitating the growth of our collaborators including their expansion into their own manufacturing facility as they progress towards commercial scale manufacturing from our Stevenage Manufacturing Innovation Centre.

CGT Catapult Braintree facility to become a crucial UK ATMP innovation asset

After delivering on its initial remit to support the COVID-19 pandemic response, the CGT Catapult Braintree site is set to become a unique centre for innovation in cell and gene therapy manufacturing.

The future of the ATTC network

To continue delivering life-saving treatments to patients across the UK, CGT Catapult is looking to secure additional funding to further expand the network.



Sustainability, equality, diversity and inclusion

With the substantial growth in the CGT Catapult workforce, we continue to focus our internal operations on our environmental footprint and employee inclusion as well as maintaining parity in gender pay gap.

This year we achieved carbon neutral status as a result of carbon offsetting, and are working towards becoming a net zero organisation.

Once we have made significant progress ourselves towards net zero and reached deeper into national communities through our actions on equality, diversity, inclusion and place we will examine how we can use our knowledge to help others in the industry.



Expanding UK ATMP activities in Scotland and Northern England

In setting up a new CGT Catapult facility in Edinburgh, we are planning to further enable industry growth across the UK, expanding collaborations from universities and Contract Research Organisations to accelerate product development, clinical trials and adoption.



Post-Brexit opportunities

Now that the UK has left the EU, CGT Catapult will leverage investment opportunities in a freely accessible market with streamlined regulations, accelerated access and licensing schemes while continuing to maintain high international standards.



Financial highlights

The financial information in this review represents the year-end position for the Cell Therapy Catapult Limited group for the year ending 31st March 2021

Income

For the year ended 31st March 2021	2021 £'000s	2020 £'000s	2019 £'000s
Innovate UK core grant funding	14,200	15,800	26,800
Third party grant funding	34,500	8,100	4,500
Industrial income	21,200	14,900	7,000
Total	69,900	38,800	38,300

Balance sheet

For the year ended 31st March 2021	2021 £'000s	2020 £'000s	2019 £'000s
Fixed assets	74,600	56,300	53,200
Net current assets	28,300	12,500	9,800
Creditors	(17,100)	(7,000)	(7,000)
Provisions for liabilities	(13,600)	(10,300)	(8,700)
Net assets	72,200	51,500	47,300
Capital and reserves	72,200	51,500	47,300

Cell and Gene Therapy Catapult is the trading name of Cell Therapy Catapult Limited (limited by guarantee), registered in England and Wales under company number 08964711 with registered office at 12th Floor Tower Wing B, Guy's Hospital, Great Maze Pond, London SE1 9RT.

Corporate governance

Cell Therapy Catapult Limited is an independent, not-for profit company limited by guarantee.

CGT Catapult receives substantial grants from Innovate UK and works in coordination with them while remaining independent and self-governing.

Our committees as of April 2021

We have established three committees that meet independently and make recommendations for the Board.

CGTC Nomination Committee members

- ▶ John Brown
- ▶ Stuart Henderson
- ▶ Nick Higgins
- ▶ Hilary Newiss

Operating subsidiaries

Cell Therapy Catapult Services Limited and the CGTC Manufacturing Innovation Centre Ltd.

CGTC Remuneration Committee members

- ▶ Nick Higgins
- ▶ Steven Chatfield
- ▶ Hilary Newiss
- ▶ Christine Soden
- ▶ Marc Turner

CGTC Audit Committee members

- ▶ Stuart Henderson
- ▶ Steven Chatfield
- ▶ Bruce Keogh
- ▶ Christine Soden
- ▶ Angela Thomas
- ▶ Marc Turner

Non-Executive Directors



*Dr John Brown
CBE, FRSE Chairman*



*Dr Ian Campbell
Director*



*Dr Steven Chatfield
Director*



*Prof. Uta Griesenbach
Director*



*Stuart Henderson
Director*



*Nick Higgins
Director*



*Prof. Sir Bruce Keogh
Director*



*Hilary Newiss
Director*



*Christine Soden
Director*



*Prof. Angela Thomas
Director*



*Prof. Marc Turner
Director*

Executive Team



*Matthew Durdy
Chief Executive Officer*



*Dr Jonathan Appleby
Chief Scientific Officer*



*Dr Jacqueline Barry
Chief Clinical Officer*



*Dr Sharon Brownlow
Chief Business Officer*



*Brian Collins
Chief Financial Officer*



*Dr Nick Johnson
Chief Strategy and
Impact Officer*



*Dr Stephen Ward
Chief Manufacturing Officer*

Thank you to the people who have worked with us over the year:

- ▶ CGT Catapult staff
- ▶ National and international organisations
- ▶ National and international companies
- ▶ National Health Services
- ▶ Regulators
- ▶ Academic and industry research teams
- ▶ Funding investors

Cell and Gene Therapy Catapult is committed to ensuring high standards of research integrity and research best practice in the activities we carry out. We subscribe to the principles described in the UK concordat to support research integrity.

Cell and Gene Therapy Catapult is a trading name of Cell Therapy Catapult Limited, registered in England and Wales under company number 07964711, with registered office at 12th Floor Tower Wing, Guy's Hospital, Great Maze Pond, London, SE1 9RT. VAT number 154421433.

CATAPULT

Cell and Gene Therapy

Thank you to the people we have worked with over the year, including:

Funders and investors



National and International organisations



Regulators



National Health Service



Researchers



National and international companies



Cell and Gene Therapy Catapult

12th Floor Tower Wing
Guy's Hospital,
Great Maze Pond
London SE1 9RT

+44 (0)20 3728 9500
info@ct.catapult.org.uk
ct.catapult.org.uk
Twitter: @CGTCatapult

